FDA rejects wider use of Theravance's telavancin

11/30/2009 | Reuters

Theravance failed to gain FDA approval to market telavancin, an injectable antibiotic, as a treatment for nosocomial pneumonia. The drug developer said it has the information and analyses needed to address the agency's complete-response letter.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC